{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Number of patients with serious adverse events possibly related, probably related or definitely related to the study treatment","groups":[{"description":"Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.\n\nstereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses","id":"OG000","title":"Group 1 (CK SRS Boost Therapy)"},{"description":"Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.\n\nstereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses","id":"OG001","title":"Group 2 (CK SRS Salvage Therapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One subject in the Boost Arm was withdrawn prior to Cyberknife therapy due to disease progression and was therefore not analyzed.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Rates of Adverse Events Associated With Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}